Coeptis Therapeutics Holdings Inc (COEP) Stock: What Does the Chart Say Friday?

Overall market sentiment has been high on Coeptis Therapeutics Holdings Inc (COEP) stock lately. COEP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Coeptis Therapeutics Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COEP!

See Full COEP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With COEP Stock Today?

Coeptis Therapeutics Holdings Inc (COEP) stock is lower by -2.83% while the S&P 500 is higher by 0.33% as of 10:59 AM on Friday, Nov 10. COEP has fallen -$0.03 from the previous closing price of $1.06 on volume of 64,178 shares. Over the past year the S&P 500 has risen 16.35% while COEP has fallen -55.02%. COEP lost -$3.47 per share in the over the last 12 months. To screen for more stocks like Coeptis Therapeutics Holdings Inc click here.

More About Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. Click Here to get the full Stock Report for Coeptis Therapeutics Holdings Inc stock.